{"name":"IQVIA Holdings","slug":"iqvia","ticker":"IQV","exchange":"NYSE","domain":"iqvia.com","description":"IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including reta","hq":"Durham, NC, USA","founded":0,"employees":"93000","ceo":"Ari Bousbib","sector":"Clinical CRO / Data Analytics","stockPrice":174.28,"stockChange":3.66,"stockChangePercent":2.15,"marketCap":"$29.6B","metrics":{"revenue":15200000000,"revenueGrowth":10.3,"grossMargin":33.3,"rdSpend":3337000,"netIncome":1360000000,"cash":2140999936,"dividendYield":0,"peRatio":22.2,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Tafinlar patent cliff ($1.4B at risk)","drug":"Tafinlar","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Mekinist patent cliff ($1.3B at risk)","drug":"Mekinist","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-23","type":"earnings","headline":"IQVIA Holdings Reports Fourth-Quarter and Full-Year 2022 Results","summary":"IQVIA Holdings reported fourth-quarter and full-year 2022 results, with revenue increasing 10.3% year-over-year to $3.6 billion.","drugName":"","sentiment":"positive"},{"date":"2022-09-01","type":"deal","headline":"IQVIA Holdings Acquires Novotech","summary":"IQVIA Holdings acquired Novotech, a leading clinical research organization, to expand its capabilities in clinical trial management.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOYUZaRmZZSVhwV0dqT2hxaUV5YUpKWEdJY0xTbkFyVDZqSk8zU1RpRlUxOGVSMDBrOHRzQ3dfWWFZSG9CckgzMnFELW16TWZON2hXQXNybmNvaEJYYlEzaXJtQzdsZEtOMFJXemZGcnV1dmIyZmhfUW9ZV2xDdTlSMkNXckV4cFI2N19aTjZCNUQ0aHRRMGhhSDZXcjlSalE3Sk9LRFFfcGF3ODNENkE?oc=5","date":"2026-04-08","type":"pipeline","source":"Sahm","summary":"IQVIA.ai Launch With Nvidia Puts AI At Core Of Pharma Ties - Sahm","headline":"IQVIA.ai Launch With Nvidia Puts AI At Core Of Pharma Ties","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"pipeline","source":"simplywall.st","summary":"IQVIA.ai Launch With Nvidia Puts AI At Core Of Pharma Ties - simplywall.st","headline":"IQVIA.ai Launch With Nvidia Puts AI At Core Of Pharma Ties","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-24","type":"pipeline","source":"simplywall.st","summary":"Is IQVIA.ai’s NVIDIA‑Powered Platform Altering The Investment Case For IQVIA Holdings (IQV)? - simplywall.st","headline":"Is IQVIA.ai’s NVIDIA‑Powered Platform Altering The Investment Case For IQVIA Holdings (IQV)?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOTDd5WTFHcXliNkxpOWZwUVlYanpUa2tCYUlsQndLQVhRSHF0cllNMGMxSkxZaHZrYUo1TnIyZ3JKMTE0TjhvUXl2QWdpTmhSdGFIZnNhUXh2bGFURVhkMVk5MEFNSzlFVHdpaGs0d0M3cVVQVWhjaWp5dW56NTdHbzlPSnZhQ0Ezdlo1TlVn?oc=5","date":"2026-03-11","type":"pipeline","source":"Yahoo Finance","summary":"IQVIA Expands In Vitro Discovery Footprint As Shares Face Pressure - Yahoo Finance","headline":"IQVIA Expands In Vitro Discovery Footprint As Shares Face Pressure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxORFU5V0RSY0RLcTJVQ2ZJd3RJN0dIU3o1ajFSQkd2WlhXZHRXTEtEOEtvd2MyVkdPVGhtOUJhclJhdFJ4bm1FWldtazhoSkxuZVJmc3VNTkg3T0xKQzR1V2JLUGRpY0d4V2NQY20wNU1lR3RIWm55NThaanRYX21JOE40cHJuVDdOT21TTXIxNzVybVoyMTI1SjFrTFNrcHNpZktzR3ZadmYtTnhMVEFEcmNsTXREQXoyZjFqblZBZzJzSlBJZkR1c0pZMDNIM0prZ1BRWVlUaw?oc=5","date":"2026-03-04","type":"pipeline","source":"Finviz","summary":"Jim Cramer on IQVIA: \"I Like the Business Very Much, I Just Don't Know Whether This Is the Right Stock to Play It\" - Finviz","headline":"Jim Cramer on IQVIA: \"I Like the Business Very Much, I Just Don't Know Whether This Is the Right Stock to Play It\"","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQUlZ5eDRtZlg2Nk1ObS0yS3ZsU1NWaTRVdGFtZlRYYWp3cy1lLWpJWjVzVGdiZnVvQkVaTTgzWk5MUnp3LXVrb2Nka0kzM3ZzVjNwSUV0V2hQRHlUeHk2UmhGeVotSnJuZXRPdk9mT2U2T1pLY3dIcnhac1RXanpHQ1gzU3owZGpIeHpyTkJtQ3IxTDFwLWlSY2JzSHJpb2ZONF9hSTZ6UDJwZkd2Skp0TWVrSjViYzdtZGc?oc=5","date":"2026-03-02","type":"deal","source":"TIKR.com","summary":"IQVIA Acquires Charles River Assets for $145 Million: Here’s the Street’s Scenario for 70% Upside - TIKR.com","headline":"IQVIA Acquires Charles River Assets for $145 Million: Here’s the Street’s Scenario for 70% Upside","sentiment":"neutral"},{"date":"2026-02-17","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQb2QyQnNMOURqZllnbkVqcFEzalhCRDJmNXdLajVZRXI3c0hFUXg5RXRSTjNpUzRadWx4X1ZFaFV0am1oRWdsSjVud25aRmZFVGxGWWhRTnJkT3BVYWNQQkVpV25pWXVXUndlZFJFT3IwbVZ2N0JxNnE4UHg3aGgxVXh0dnpoS0ktTGFoS3oyUnF6aV94aHdwYkE5ZVBkb2tlTzU0MVRZS0szRV9wcjA1enI1YVc2YUYyMFdpcGR3?oc=5","date":"2026-01-03","type":"pipeline","source":"AD HOC NEWS","summary":"IQVIA Holdings Is Quietly Eating Wall Street – But Should You Jump In Now? - AD HOC NEWS","headline":"IQVIA Holdings Is Quietly Eating Wall Street – But Should You Jump In Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1QbGVaRG1Hbmlnc0VGcEI1emkxTnB5dVdCZGpqRXVaODJsb050V2owVkRjcTBJVlBGTlpVLXR4TkllZC0zU3RxclJpSmZrUXVtZHlFb29vOEVBQkZacFRUXzN2RWlMTk1HanZhY295SmF5OFZFZmdxVnBjRQ?oc=5","date":"2025-10-30","type":"earnings","source":"Yahoo Finance","summary":"IQVIA Holdings Inc (IQV) Q3 2025 Earnings Call Highlights: Record Free Cash Flow and Strong ... - Yahoo Finance","headline":"IQVIA Holdings Inc (IQV) Q3 2025 Earnings Call Highlights: Record Free Cash Flow and Strong ...","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBQVl9qTUhtUjctRUtmdXJ5ZXM4LUxtanJLdGh0MGJqWGdmZmExbHZpb3NlMHU4RW5DUUFNSWd4TjNzNUtXaGtrWUtMRXRDOEJVSFJkd2gzLXF1QmJoSVdRa2VJTWE2clVjREI3WXdiZ1BVc1JNUXRr?oc=5","date":"2025-10-28","type":"earnings","source":"fortune.com","summary":"IQVIA Holdings (IQV) Q3 2025 Earnings Call Transcript - fortune.com","headline":"IQVIA Holdings (IQV) Q3 2025 Earnings Call Transcript","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOSXQ4eU83YUFiMHZLb0poTUZaY0F5d3k3SExvd0xkekRoRGxiNkZoTjdrQ2VVMGRBVVppajNkZ196ZmpuOEVZb1RwVklTVWtWT1Jva2UweTFHYUFJcXQwdFl0Mmo3NU9YLUppV1pFTHdCZkUteUJkbnVRaHdxNzZwOXJVQWNLSVctdG15OG83aTFKenZKekpoQzJhOWdFU3g5SjlVYzR2eWZjYkZma0ZjZUp0ZXdPVXRtTjl3OEU5a3VCYjFzMUw0SXB1Vk0?oc=5","date":"2025-09-02","type":"pipeline","source":"Investing.com","summary":"IQVIA’s SWOT analysis: healthcare giant faces headwinds amid industry shifts - Investing.com","headline":"IQVIA’s SWOT analysis: healthcare giant faces headwinds amid industry shifts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNOG5OMHlRNUc5TnlfZXVPUHQyUDc3S0ZNbWY1VW8ydzJuMTRWZDVFcXNMc3oxY0MtTS1FazlWbGlJN2lrbzUtWGRiSzA0cnBSeXJ2dE5lSlpWSFpxU2pWNVpzTVFFaWpYalNQc3RXVkJsZ3dPTHBoQlR4NkpDTFJ4bG4zNA?oc=5","date":"2025-07-22","type":"pipeline","source":"Investor's Business Daily","summary":"Medtech Skyrockets 50%-Plus On 'Shockingly Strong' Report - Investor's Business Daily","headline":"Medtech Skyrockets 50%-Plus On 'Shockingly Strong' Report - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWlJvQmw1VnJNd0JYdkQ2ekhLcWlOUnU1Q2QzczhpM1ZKMnA4QTlzOHFOcENsN2QzRml6eFNNMk5jdmVVc2ZsZ1IzY0NOR2R0NDlHcndYb3ZUc2FmUVc0UUdqSllLQ3lsWEdkem9qLW1lQ0V6SC1Pd1p6MUJ6MldGQXZaSlhGYjA0aHFmQUtjQTdLc1F5cXZBNC0ycjlneXZwcldEbTZCNWM?oc=5","date":"2025-07-16","type":"pipeline","source":"Seeking Alpha","summary":"IQVIA: Competition Is Creating More Challenges Over The Long Haul (NYSE:IQV) - Seeking Alpha","headline":"IQVIA: Competition Is Creating More Challenges Over The Long Haul (NYSE:IQV)","sentiment":"neutral"}],"patents":[{"drugName":"Tafinlar","drugSlug":"dabrafenib","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Mekinist","drugSlug":"trametinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1300000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Parexel","Icon","Labcorp"],"therapeuticFocus":["Oncology","Cardiovascular"],"financials":{"source":"sec_edgar","revenue":9739000000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":9739000000,"period":"2017-12-31"},{"value":6878000000,"period":"2016-12-31"},{"value":6878000000,"period":"2016-12-31"},{"value":5737619000,"period":"2015-12-31"},{"value":5737000000,"period":"2015-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":3337000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":1360000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":29944000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":174.28,"previousClose":170.62,"fiftyTwoWeekHigh":247.05,"fiftyTwoWeekLow":134.65,"fiftyTwoWeekRange":"134.65 - 247.05","fiftyDayAverage":181.4,"twoHundredDayAverage":196.17,"beta":1.39,"enterpriseValue":43245215744,"forwardPE":12.4,"priceToBook":4.55,"priceToSales":1.81,"enterpriseToRevenue":2.65,"enterpriseToEbitda":14.72,"pegRatio":0.72,"ebitda":2937999872,"ebitdaMargin":18,"freeCashflow":2216624896,"operatingCashflow":2654000128,"totalDebt":16305000448,"debtToEquity":245.9,"currentRatio":0.75,"returnOnAssets":5.1,"returnOnEquity":21.4,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":20,"targetMeanPrice":234.25,"targetHighPrice":287,"targetLowPrice":200,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.1,"institutionHeldPercent":103.6,"sharesOutstanding":167866339,"floatShares":161248940,"sharesShort":4208744,"shortRatio":1.69,"shortPercentOfFloat":2.5,"epsTrailing":7.84,"epsForward":14.07,"revenuePerShare":94.88,"bookValue":38.34,"officers":[{"age":64,"name":"Mr. Ari  Bousbib","title":"CEO & Chairman"},{"age":61,"name":"Mr. Eric M. Sherbet J.D.","title":"Executive VP, General Counsel & Secretary"},{"age":62,"name":"Mr. W. Richard Staub III","title":"President of Research & Development Solutions"},{"age":51,"name":"Mr. Alistair  Grenfell","title":"President of Commercial Solutions"},{"age":49,"name":"Mr. Michael J. Fedock MBA","title":"Executive VP & Chief Financial Officer"},{"age":51,"name":"Mr. James G. Berkshire","title":"Executive Vice President of Global Infrastructure & Operations"},{"age":40,"name":"Ms. Keriann  Cherofsky","title":"Senior VP, Corporate Controller & Chief Accounting Officer"},{"age":null,"name":"Dr. Jeffrey A. Spaeder M.D.","title":"Chief Medical & Scientific Officer"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.iqvia.com","phone":"919 998 2000"}}